Analysts Set Novo Nordisk A/S (NYSE:NVO) Target Price at $65.56

Novo Nordisk A/S (NYSE:NVO) has earned an average rating of “Hold” from the twenty-three brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, eighteen have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $65.5625.

A number of equities analysts recently issued reports on NVO shares. Wall Street Zen upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research report on Tuesday, March 3rd. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Finally, Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target for the company.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk is being highlighted as one of the more undervalued foreign stocks, with recent results showing a profit beat and a slightly raised full-year outlook, helped by early demand for its Wegovy weight-loss pill in the U.S. Novo Nordisk (NVO) Among Our Most Undervalued Foreign Stocks to Buy Now
• Positive Sentiment: The company announced new cardiometabolic pipeline data, including Phase 3 CagriSema results and additional abstracts for the ADA 2026 meeting, which could strengthen investor confidence in future obesity and diabetes growth drivers. Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
• Positive Sentiment: Novo Nordisk is nearing EU approval for oral Wegovy, which could expand access, improve convenience, and support longer-term sales growth. Novo Nordisk Nears EU Nod For Oral Wegovy And Investor Opportunity
• Positive Sentiment: Management also launched a share repurchase program, a shareholder-friendly move that can help support the stock. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Several articles compared Novo Nordisk with Eli Lilly and Amgen, keeping attention on GLP-1 competition, pipeline depth, and valuation rather than pointing to any immediate fundamental shock. Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
• Negative Sentiment: Brazil approved the first generic copy of Ozempic, signaling new competition in a key growth category and adding pressure to Novo Nordisk’s pricing power. Brazil Clears First Generic Copy of Novo Nordisk’s Ozempic Shot
• Negative Sentiment: Broader healthcare weakness also weighed on the group, with the sector finishing lower in late trading, which may have added short-term pressure to NVO. Sector Update: Healthcare Stocks Decline Late Afternoon

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $44.59 on Friday. The firm has a market capitalization of $199.10 billion, a price-to-earnings ratio of 10.47, a price-to-earnings-growth ratio of 3.94 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The business has a fifty day moving average of $40.67 and a 200 day moving average of $46.38. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, research analysts expect that Novo Nordisk A/S will post 3.46 earnings per share for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of institutional investors have recently modified their holdings of NVO. Franklin Resources Inc. raised its stake in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $287,660,000. Capital International Investors increased its holdings in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares in the last quarter. Boston Partners purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $310,199,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Novo Nordisk A/S by 99.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.